Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.

ABSTRACT:

Purpose

To compare rates and identify predictive factors for events that represent worsening of proliferative diabetic retinopathy (PDR) in eyes treated with panretinal photocoagulation (PRP) or ranibizumab.

Design

Randomized clinical trial (55 United States sites).

Participants

Three hundred ninety-four study eyes from 305 adults with PDR, visual acuity (VA) 20/320 or better, and no history of PRP.

Intervention

Panretinal photocoagulation or intravitreous ranibizumab injections (0.5 mg/0.05 ml).

Main outcome measures

Time from randomization to a composite PDR-worsening outcome defined as the first occurrence of vitreous hemorrhage, retinal detachment, anterior segment neovascularization, or neovascular glaucoma.

Results

Through 2 years, the cumul

SUBMITTER: Bressler SB 

PROVIDER: S-EPMC6648671 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature